A way to block a pain pathway in animal models of chronic neuropathic pain including pain caused by chemotherapeutic agents and bone cancer pain suggesting a promising new approach to pain relief.
In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health (NIH) and other academic institutions have discovered a way to block a pain pathway in animal models of chronic neuropathic pain including pain caused by chemotherapeutic agents and bone cancer pain suggesting a promising new approach to pain relief.
The scientific efforts led by Salvemini, who is professor of pharmacological and physiological sciences at SLU, demonstrated that turning on a receptor in the brain and spinal cord counteracts chronic nerve pain in male and female rodents. Activating the A3 receptor – either by its native chemical stimulator, the small molecule adenosine, or by powerful synthetic small molecule drugs invented at the NIH – prevents or reverses pain that develops slowly from nerve damage without causing analgesic tolerance or intrinsic reward (unlike opioids).
An Unmet Medical Need
Pain is an enormous problem. As an unmet medical need, pain causes suffering and comes with a multi-billion dollar societal cost. Current treatments are problematic because they cause intolerable side effects, diminish quality of life and do not sufficiently quell pain.
The most successful pharmacological approaches for the treatment of chronic pain rely on certain “pathways”: circuits involving opioid, adrenergic, and calcium channels.
For the past decade, scientists have tried to take advantage of these known pathways – the series of interactions between molecular-level components that lead to pain. While adenosine had shown potential for pain-killing in humans, researchers had not yet successfully leveraged this particular pain pathway because the targeted receptors engaged many side effects.
A Key to Pain Relief
In this research, Salvemini and colleagues have demonstrated that activation of the A3 adenosine receptor subtype is key in mediating the pain relieving effects of adenosine.
“It has long been appreciated that harnessing the potent pain-killing effects of adenosine could provide a breakthrough step towards an effective treatment for chronic pain,” Salvemini said. “Our findings suggest that this goal may be achieved by focusing future work on the A3AR pathway, in particular, as its activation provides robust pain reduction across several types of pain.”
The Latest on: Pain relief
[google_news title=”” keyword=”Pain relief” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pain relief
- Questions About Tooth Pain? Doctors Have The Answer.on May 19, 2024 at 5:49 am
This article provides an overview of the best treatments for severe tooth pain based on common causes, such as tooth decay, dental abscess, dental trauma, and impacted wisdom teeth. This article ...
- What To Know and Do About Arthritis Painon May 18, 2024 at 10:00 am
Arthritis is a condition that causes pain, stiffness, and inflammation in your joints. Fortunately, medications and home remedies can help relieve pain.
- Neet Launches Topical CBD Oils for Pain Reliefon May 17, 2024 at 9:43 am
Unveiling a game changer in pain relief, Neet has launched two topical products: Neet Daily Joint+ and Neet Daily NeuPain Gone. These innovative solutions offer relief through the healing prowess of ...
- The Rise of Non-Opioid Pain Management: How EXPAREL is Revolutionizing Recoveryon May 17, 2024 at 5:20 am
How EXPAREL is Revolutionizing Recovery. According to the American College of Surgeons, 15 million Americans undergo surgery each year. Des ...
- Treating chronic pain requires much more than medicationson May 16, 2024 at 9:48 am
When it comes to adults living with chronic pain, insurance companies are short-sighted and fail to acknowledge the science showing excellent long-term outcomes of an integrated approach to treatment.
- South Rampart Pharma's quest to deliver innovative non-opioid pain solutionson May 16, 2024 at 7:19 am
Details of a unique non-opioid pain relief mechanism called SRP-001 were announced today (May 16) in a paper in Scientific Reports.
- South Rampart Pharma Publishes SRP-001's Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reportson May 16, 2024 at 3:00 am
SRP-001 is a novel, non-opioid new chemical entity without abuse, liver, and kidney toxicities present in current pain medications Publication introduces SRP-001 as a safer alternative to existing ...
- Causes, symptoms, and treatment options for arthritis in the toeson May 15, 2024 at 5:00 pm
Arthritis is a condition that affects the joints and causes pain, swelling, and stiffness. There are several forms of arthritis that can affect the toes. Treatment may include pain relievers, ice ...
- What Are Your Chronic Pain Relief Optionson May 15, 2024 at 7:34 am
Chronic pain is a condition that impacts many lives, often misunderstood by those who have never experienced it. It is not simply a symptom.
- Guernsey doctors told to phase out pain relief plasterson May 15, 2024 at 12:54 am
Doctors in Guernsey have been told to "stop or greatly reduce" prescribing lidocaine plasters. Over the last 12 months £100,000 was spent on these plasters, which are typically used to relieve nerve ...
via Bing News